Back to Studies
IMPAACT 2035/HVTN 604 / LEAP
Phase I/II Study of the Safety and Immunogenicity of VPM1002 Vaccination and BCG Revaccination against Tuberculosis in South African Pre-Adolescents Living with and without HIV
Study Status
In Development
Locality
Non-US
DAIDS Number
38846
Primary Protocol Team Members
Summary
IMPAACT 2035/HVTN 604: LEAP (Leveraging Early Adolescence to Prevent TB) is a Phase I/II double-blinded, placebo-controlled, randomized (1:1:1) multi-center trial study of the novel TB vaccine candidate VPM1002 and BCG re-vaccination. The study is designed to evaluate the safety and immunogenicity of VPM1002 vaccination and BCG re-vaccination in pre-adolescents with and without HIV and with and without Mycobacterium tuberculosis infection over 12 months.
Loading study documents...
Loading study sites...
Loading study protocol team...
Loading study press...
Loading study publications/presentations...